pharma · Eosinophilic esophagitis · Narcolepsy
Bioprojet
Bioprojet Pharma
Bioprojet Pharma is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Eosinophilic esophagitis, Narcolepsy, narcolepsy with cataplexy, Narcolepsy, Narcolepsy, Narcolepsy with catap
9 rue Rameau, Paris, 75002, FR HQ
166 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 9 rue Rameau, Paris, 75002, FR
- Employees
- 166
- Programs
- 11
- Drugs
- 19
- Patents
- 9
P22-03
Phase 1 · other · Eosinophilic esophagitis
P22-03 for Eosinophilic esophagitis is a Phase 1 program (other) at Bioprojet Pharma with 1 ClinicalTrials.gov record(s).
Internal code P22-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bioprojet Pharma
- Phase
- Phase 1
- Modality
- other
- Indication
- Eosinophilic esophagitis
- Status
- active
- Trials
- 1